$26.05
3.23% yesterday
Nasdaq, Jun 11, 10:13 pm CET
ISIN
US03209R1032
Symbol
AMPH

Amphastar Pharmaceuticals Inc Stock price

$26.05
+1.71 7.03% 1M
-17.52 40.21% 6M
-11.08 29.84% YTD
-15.09 36.68% 1Y
+6.40 32.57% 5Y
+9.45 56.93% 10Y
+17.30 197.71% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.87 3.23%
ISIN
US03209R1032
Symbol
AMPH

Key metrics

Market capitalization $1.23b
Enterprise Value $1.60b
P/E (TTM) P/E ratio 9.20
EV/FCF (TTM) EV/FCF 10.62
EV/Sales (TTM) EV/Sales 2.18
P/S ratio (TTM) P/S ratio 1.68
P/B ratio (TTM) P/B ratio 1.65
Revenue growth (TTM) Revenue growth 8.05%
Revenue (TTM) Revenue $730.66m
EBIT (operating result TTM) EBIT $194.70m
Free Cash Flow (TTM) Free Cash Flow $150.23m
Cash position $236.88m
EPS (TTM) EPS $2.83
P/E forward 9.46
P/S forward 1.70
EV/Sales forward 2.21
Short interest 16.84%
Show more

Is Amphastar Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Amphastar Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

Buy
33%
Hold
67%

Financial data from Amphastar Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
731 731
8% 8%
100%
- Direct Costs 362 362
17% 17%
49%
369 369
0% 0%
51%
- Selling and Administrative Expenses 97 97
15% 15%
13%
- Research and Development Expense 64 64
5% 5%
9%
208 208
5% 5%
28%
- Depreciation and Amortization 13 13
25% 25%
2%
EBIT (Operating Income) EBIT 195 195
7% 7%
27%
Net Profit 142 142
8% 8%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Amphastar Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amphastar Pharmaceuticals Inc Stock News

Neutral
Accesswire
21 days ago
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals websi...
Neutral
Investors Business Daily
24 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Seeking Alpha
about one month ago
Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches.  Is the stock cheap enough to buy the recent dip in the shares?
More Amphastar Pharmaceuticals Inc News

Company Profile

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Head office United States
CEO Yong Zhang
Employees 2,028
Founded 1996
Website amphastar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today